Objective: This study assessed the efficacy of conbercept for patients with non-proliferative diabetic retinopathy (NPDR). Methods: In this retrospective clinical study, 54 patients with NPDR (54 eyes) were treated with intravitreal injection of conbercept using a 3þ pro re nata regimen and followed up for 12 months. Best corrected visual acuity (BCVA), central foveal thickness (CFT), area of hard exudate (HE), and number of microaneurysms (MAs) were used as indicators of therapeutic effects. Systemic adverse reactions were recorded to assess safety. Results: During the 12-month follow-up period, the mean number of injections was 6.12 AE 1.89 on demand. From baseline to the 12-month follow-up, the BCVA of patients with NPDR increased from 0.71 AE 0.20 logMAR to 0.43 AE 0.16 logMAR, CFT decreased from 424.26

Objective: To assess the clinical efficacy of sustained-release dexamethasone (DEX) , conbercept and laser photocoagulation on macular edema （ME） secondary to BRVO.Methods: 159 ischemic BRVO eyes were enrolled and randomly divided into sustained-release DEX group (30 eyes), CBC group (51 eyes), combination group (DEX+CBC, 29 eyes), and laser group (49 eyes). and received single intravitreal injection of sustained-release DEX (0.7 mg), CBC (0.05 ml) [3+PRN], sustained-release DEX (0.7 mg) combined with CBC (0.05 ml), and laser photocoagulation therapy respectively. The changes of the central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were observed. Additionally, the number of HRD was calculated.Results: After treatment, CFT significantly decreased and BCVA significantly increased in DEX, CBC and combination groups (all P<0.01). Moreover, the number of HRD in three intravitreal injection groups was significantly reduced compared with pre-treatment (all P<0.01).Conclusion: Intravitreal injection of sustained-release DEX, CBC and combined treatment could alleviate BRVO-related ME, reduce CFT , and improve patients’ visual acuity . The retinal HRD number decreased after all intravitreal injections . In addition, there were non-responders in all intravitreal treatment groups, and the mean baseline HRD number of non-responder group was higher than that of responder group.

Background: This study aimed to assess efficacy differences of aflibercept by intravitreal injection for diabetic macular edema (DME) with different OCT types. Methods: according to OCT morphology, 128 patients (128 eyes) with DME were divided into the diffuse retinal thickening (DRT; 41 patients, 41 eyes), cystoid macular edema (CME; 47 patients, 47 eyes), and serous retinal detachment (SRD; 40 patients, 40eyes) groups. All patients were treated by intravitreal injection of 0.5 mg (0.05 mL) aflibercept according to the 3+prn regimen. BCVA (LogMAR) and central foveal thickness (CFT) among the three groups at baseline, and 1 month, 3 months, 6 months and 12 months after treatment, respectively, were assessed. Results: At 1 month, 3 months, 6 months and 12 months after treatment, improvements in BCVA and CFT in the three groups showed statistical significance (P<0.05). BCVA improvement was better at all time points in the DRT group compared with the SRD group (P<0.05). BCVA improvement was also better in the CME group compared with the SRD group at 6 months and 12 months post-treatment (P<0.05). At 1 month, 3 months and 6 months after treatment, CFT differences among the three groups had no statistical significance (P>0.05), while at 12 months post-treatment, CFT values among the three groups had significant differences (F=3.77, P=0.0269). at 12 months after treatment, CFT improvement was better in the DRT and CME groups compared with the SRD group (P<0.05). Conclusion: aflibercept by intravitreal injection could significantly improve visual acuity in DME patients with different OCT types and reduce CFT. At the initial treatment of 12 months, CFT and BCVA improvements in the DRT and CME types were the most pronounced.